Those speaking during the second and final day of the FDA's public hearings regarding the promotion of regulated products on websites and social-media sites weren't nearly as enamored of the technology as those speaking on the first day. And they weren't inclined to give the pharmaceutical industry much leeway.
Critics Say Social-Media Should Be Off Limits for DTC Drug Ads
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.